LIVIVO - Search results -

Search results

Result 1 - 10 of total 157

Search options

Article ; Online: Mismatch repair status and gastro-oesophageal dysplasia: need for a dedicated gastrointestinal pathologist?

Angerilli, Valentina / Lonardi, Sara / Farinati, Fabio / Savarino, Edoardo / Bergamo, Francesca / Fassan, Matteo

2022 Volume 80, Issue 7, Page(s) 1138–1140

MeSH term(s)	Carcinoma in Situ ; DNA Mismatch Repair ; Esophageal Neoplasms ; Gastroesophageal Reflux ; Humans ; Pathologists ; Stomach
Language	English
Publishing date	2022-04-05
Publishing country	England
Document type	Letter
ZDB-ID	131914-0
ISSN	1365-2559 ; 0309-0167
ISSN (online)	1365-2559
ISSN	0309-0167
DOI	10.1111/his.14647
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1328: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Lynch syndrome-related colorectal carcinomas are NTRK-negative.

Remo, Andrea / Grillo, Federica / Vanoli, Alessandro / Parente, Paola / Mastracci, Luca / Angerilli, Valentina / Urso, Emanuele Damiano / Bergamo, Francesca / Fassan, Matteo

Histopathology

2023 Volume 83, Issue 2, Page(s) 335–336

MeSH term(s)	Humans ; Colorectal Neoplasms, Hereditary Nonpolyposis/genetics ; Colorectal Neoplasms/genetics ; Mutation ; MutL Protein Homolog 1/genetics ; DNA Methylation ; Microsatellite Instability ; DNA Mismatch Repair
Chemical Substances	MutL Protein Homolog 1 (EC 3.6.1.3)
Language	English
Publishing date	2023-05-17
Publishing country	England
Document type	Letter
ZDB-ID	131914-0
ISSN	1365-2559 ; 0309-0167
ISSN (online)	1365-2559
ISSN	0309-0167
DOI	10.1111/his.14944
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1328: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: What do cancer patients experience of the simultaneous care clinic? Results of a cross-sectional study on patient care satisfaction.

Galiano, Antonella / Feltrin, Alessandra / Pambuku, Ardi / Lo Mauro, Leda / De Toni, Chiara / Murgioni, Sabina / Soldà, Caterina / Maruzzo, Marco / Bergamo, Francesca / Brunello, Antonella / Zagonel, Vittorina

Cancer medicine

2024 Volume 13, Issue 3, Page(s) e7000

Abstract: Background: Veneto Institute of Oncology has activated a simultaneous care outpatient clinic (SCOC) in which cancer patients with advanced-stage cancer are evaluated by oncologist and palliative care specialists. This cross-sectional study investigated ... ...

Abstract	Background: Veneto Institute of Oncology has activated a simultaneous care outpatient clinic (SCOC) in which cancer patients with advanced-stage cancer are evaluated by oncologist and palliative care specialists. This cross-sectional study investigated patients' perceptions of the quality of this service. Materials and methods: An ad-hoc self-administered questionnaire, developed by SCOC team, was used to assess the satisfaction of patients admitted at SCOC consultation. The questionnaire, in addition to the socio-demographic questions, contains eight questions with the Likert scale: time dedicated, feel listened to, feel understood, feel free to speak openly and to express doubts and concerns, feeling about information and indication received, level of empathy of health care and quality of the relationship, level of professional/quality of performance and utility of consultation, and one open-ended question. The questionnaire has been proposed to all 174 consecutively admitted patients at SCOC. Results: One hundred and sixty-two patients filled in the questionnaire: 66.7% were male, median age was 71 years, 88.3% had metastatic disease. The time dedicated to SCOC consultation was judged more than adequate (55%) or adequate (35%) by 90% of subjects. Patients completely satisfied about being listened to were 92.5%, with 80.9% being completely satisfied with understanding of their issues and 92% with the freedom to speak and express doubts. Usefulness of the SCOC was rated as excellent by 40% and good by 54.4% of patients. No statistically significant differences were observed in the responses to the questions by gender, age (< or ≥70 years old) and type of tumor. Conclusion: Our study shows high levels of satisfactions after SCOC consultation in advanced cancer subjects. Patients' feedback confirmed that SCOC model was effective in helping them during their treatment journey and decision at the end of life. This study encouraged us to enhance our practice of SCOC consultation. Implications for practice: A joint evaluation of patients living with cancer by oncologist and palliative care team (SCOC-embedded model), has shown to enhance patients' experience/satisfaction with care-such as listening, understanding, receiving information, symptom control, and decision about future, independently of age, gender, and kind of tumor.
MeSH term(s)	Humans ; Male ; Aged ; Female ; Patient Satisfaction ; Cross-Sectional Studies ; Palliative Care/methods ; Neoplasms/therapy ; Ambulatory Care Facilities ; Carrier Proteins ; Membrane Proteins
Chemical Substances	SCOC protein, human ; Carrier Proteins ; Membrane Proteins
Language	English
Publishing date	2024-02-23
Publishing country	United States
Document type	Journal Article
ZDB-ID	2659751-2
ISSN	2045-7634 ; 2045-7634
ISSN (online)	2045-7634
ISSN	2045-7634
DOI	10.1002/cam4.7000
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Correction to: Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting.

Grillo, Federica / Angerilli, Valentina / Parente, Paola / Vanoli, Alessandro / Luchini, Claudio / Sciallero, Stefania / Puccini, Alberto / Bergamo, Francesca / Lonardi, Sara / Valeri, Nicola / Mastracci, Luca / Fassan, Matteo

Virchows Archiv : an international journal of pathology

2024

Language	English
Publishing date	2024-01-17
Publishing country	Germany
Document type	Published Erratum
ZDB-ID	1184867-4
ISSN	1432-2307 ; 0945-6317
ISSN (online)	1432-2307
ISSN	0945-6317
DOI	10.1007/s00428-024-03733-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud III Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches.

Ceccon, Carlotta / Angerilli, Valentina / Rasola, Cosimo / Procaccio, Letizia / Sabbadin, Marianna / Bergamo, Francesca / Malapelle, Umberto / Lonardi, Sara / Fassan, Matteo

Frontiers in oncology

2022 Volume 12, Page(s) 930108

Abstract: The introduction of immunotherapy has revolutionized the oncological targeted therapy paradigm. Microsatellite instability (MSI) identifies a subgroup of colorectal cancers (CRCs) which respond to treatment with immune checkpoint inhibitors. Tissue ... ...

Abstract	The introduction of immunotherapy has revolutionized the oncological targeted therapy paradigm. Microsatellite instability (MSI) identifies a subgroup of colorectal cancers (CRCs) which respond to treatment with immune checkpoint inhibitors. Tissue biopsy is currently the gold standard for the assessment of MSI/Mismatch Repair deficiency (MMRd) by means immunohistochemistry or molecular assays. However, the application of liquid biopsy in the clinic may help to overcome several limitations of tissue analysis and may provide great benefit to the diagnostic scenario and therapeutic decision-making process. In the context of MSI/MMRd CRC, the use of liquid biopsy may allow to establish MSI/MMR status if tissue sampling cannot be performed or in case of discordant tissue biopsies. Liquid biopsy may also become a powerful tool to monitor treatment response and the onset resistance to immunotherapy over time and to stratify of MSI/MMRd patients according to their risk of relapse and metastases. The aim of this review is to summarize the main technical aspects and clinical applications, the benefits, and limitations of the use of liquid biopsy in MSI/MMRd colorectal cancer patients.
Language	English
Publishing date	2022-06-28
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2022.930108
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Could Total Neoadjuvant Therapy Followed by Surgical Resection Be the New Standard of Care in Pancreatic Cancer? A Systematic Review and Meta-Analysis.

De Simoni, Ottavia / Scarpa, Marco / Soldà, Caterina / Bergamo, Francesca / Lonardi, Sara / Fantin, Alberto / Pilati, Pierluigi / Gruppo, Mario

Journal of clinical medicine

2022 Volume 11, Issue 3

Abstract: Background: Total neoadjuvant therapy (TNT), intended as induction chemotherapy (IC) followed by radio-chemotherapy (RCT), has been taking hold in the treatment of pancreatic ductal adenocarcinoma (PDAC). The aim of this review is to summarize the ... ...

Abstract	Background: Total neoadjuvant therapy (TNT), intended as induction chemotherapy (IC) followed by radio-chemotherapy (RCT), has been taking hold in the treatment of pancreatic ductal adenocarcinoma (PDAC). The aim of this review is to summarize the available evidence on the role of TNT followed by curative surgery. Methods: Eligible studies were those reporting on patients with PDAC undergoing curative surgery after TNT. The primary endpoint was overall survival (OS). Results: A total of 1080 patients with PDAC who had undergone TNT were analyzed. The most common IC regimen was Gemcitabine (N 620, 57%). Toxicity during IC varied from 14% to 51%. Disease progression during IC varied from 3% to 25%. 607 (62%) patients underwent curative surgery after IC + CRT. In meta-analysis, the available data on lymph node metastases radicality and 2 years OS had better results in favor of TNT groups (OR 1.77, 95% CI 1.20-2.60, Conclusions: Despite the heterogeneity of the studies, different selection criteria, and non-negligible drop-out rate, TNT demonstrated a potential superiority to NAT without CRT in oncological and pathological outcomes, even if the main differences seem to depend on the IC regimen.
Language	English
Publishing date	2022-02-03
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm11030812
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer.

Prete, Alessandra Anna / Procaccio, Letizia / Bergamo, Francesca / Rasola, Cosimo / Nappo, Floriana / Zagonel, Vittorina / Lonardi, Sara

Current oncology (Toronto, Ont.)

2022 Volume 29, Issue 2, Page(s) 544–550

Abstract: PARP inhibitors are largely recognized as active drugs in BRCA-mutated breast and ovarian malignancies. In pancreatic ductal adenocarcinoma, the PARP inhibitor olaparib has recently been approved as maintenance treatment in patients with germline BRCA ... ...

Abstract	PARP inhibitors are largely recognized as active drugs in BRCA-mutated breast and ovarian malignancies. In pancreatic ductal adenocarcinoma, the PARP inhibitor olaparib has recently been approved as maintenance treatment in patients with germline BRCA mutations reaching disease control after a platinum-based first line chemotherapy, proving significant benefit on progression free survival. On the other hand, little evidence is available regarding olaparib as single agent after progression with standard treatment in BRCA-mutated pancreatic ductal adenocarcinoma. A 61-year-old female patient harboring germline BRCA2 mutation was treated at our institution for a pancreatic ductal adenocarcinoma with lung and liver metastases. The patient received three previous lines of treatment with standard therapies, as follows: after the third line treatment failure, we started a further line of treatment with olaparib in off-label prescription. After the first two cycles, a CT scan documented partial response, with complete regression of lung metastases. The response was maintained after four cycles, with further response and clinical benefit. The radiologic and clinical response was maintained for 6 months. This case highlights the potential of olaparib as single agent after progression with standard treatment in BRCA-mutated pancreatic cancer.
MeSH term(s)	BRCA2 Protein/genetics ; Female ; Germ-Line Mutation ; Humans ; Middle Aged ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/pathology ; Phthalazines/adverse effects ; Phthalazines/therapeutic use ; Piperazines/adverse effects ; Piperazines/therapeutic use
Chemical Substances	BRCA2 Protein ; BRCA2 protein, human ; Phthalazines ; Piperazines ; olaparib (WOH1JD9AR8)
Language	English
Publishing date	2022-01-27
Publishing country	Switzerland
Document type	Case Reports ; Journal Article
ZDB-ID	1236972-x
ISSN	1718-7729 ; 1198-0052
ISSN (online)	1718-7729
ISSN	1198-0052
DOI	10.3390/curroncol29020049
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4305: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter.

Businello, Gianluca / Angerilli, Valentina / Lonardi, Sara / Bergamo, Francesca / Valmasoni, Michele / Farinati, Fabio / Savarino, Edoardo / Spolverato, Gaya / Fassan, Matteo

Updates in surgery

2022 Volume 75, Issue 2, Page(s) 291–303

Abstract: The comprehensive molecular characterization of gastric and gastroesophageal junction adenocarcinomas has led to the improvement of targeted and more effective treatments. As a result, several biomarkers have been introduced into clinical practice and ... ...

Abstract	The comprehensive molecular characterization of gastric and gastroesophageal junction adenocarcinomas has led to the improvement of targeted and more effective treatments. As a result, several biomarkers have been introduced into clinical practice and the implementation of innovative diagnostic tools is under study. Such assessments are mainly based on the evaluation of limited biopsy material in clinical practice. In this setting, the pathologist represents a key player in the selection of patients facilitating precision medicine approaches.
MeSH term(s)	Humans ; Esophagogastric Junction/pathology ; Pathologists ; Stomach Neoplasms/diagnosis ; Stomach Neoplasms/pathology ; Esophageal Neoplasms/diagnosis ; Esophageal Neoplasms/pathology ; Adenocarcinoma/diagnosis ; Adenocarcinoma/genetics ; Adenocarcinoma/pathology ; Biomarkers ; Biomarkers, Tumor
Chemical Substances	Biomarkers ; Biomarkers, Tumor
Language	English
Publishing date	2022-07-14
Publishing country	Italy
Document type	Journal Article
ZDB-ID	2572692-4
ISSN	2038-3312 ; 2038-131X
ISSN (online)	2038-3312
ISSN	2038-131X
DOI	10.1007/s13304-022-01330-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 101: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications.

Angerilli, Valentina / Sabella, Giovanna / Centonze, Giovanni / Lonardi, Sara / Bergamo, Francesca / Mangogna, Alessandro / Pietrantonio, Filippo / Fassan, Matteo / Milione, Massimo

Critical reviews in oncology/hematology

2022 Volume 172, Page(s) 103647

Abstract: Advances in molecular biology have markedly increased our understanding of the heterogeneous molecular landscape of colorectal cancer (CRC). Up to 15% of CRCs harbor the BRAF p.V600E somatic mutation (BRAFmt), a well-established negative prognostic ... ...

Abstract	Advances in molecular biology have markedly increased our understanding of the heterogeneous molecular landscape of colorectal cancer (CRC). Up to 15% of CRCs harbor the BRAF p.V600E somatic mutation (BRAFmt), a well-established negative prognostic marker in patients with metastatic CRC (mCRC). The BEACON CRC trial set a new standard of care in patients with progressive BRAFmt cancers, consisting of the combination of encorafenib and cetuximab. On these bases, BRAF mutational testing is now recommended in patients with mCRC. However, efforts are needed to further stratify patients carrying this mutation. Here, we discuss the heterogeneous pathologic and molecular landscape of BRAFmt CRCs, focusing on the promises and pitfalls of molecular diagnostics, on novel biomarkers to improve patients' stratification and on the current diagnostic scenario for CRC. We believe that a better stratification based on histopathological features and novel molecular biomarkers should be performed to optimize patient management and therapeutic decision-making.
MeSH term(s)	Adenocarcinoma/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cetuximab/therapeutic use ; Colorectal Neoplasms/diagnosis ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Humans ; Mutation ; Proto-Oncogene Proteins B-raf/genetics
Chemical Substances	BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Cetuximab (PQX0D8J21J)
Language	English
Publishing date	2022-03-04
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	605680-5
ISSN	1879-0461 ; 0737-9587 ; 1040-8428
ISSN (online)	1879-0461
ISSN	0737-9587 ; 1040-8428
DOI	10.1016/j.critrevonc.2022.103647
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1931: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study.

Prete, Alessandra Anna / Angerilli, Valentina / Bergamo, Francesca / Vettore, Valentina / De Toni, Chiara / Intini, Rossana / Cerma, Krisida / Ricagno, Gianmarco / Cerantola, Riccardo / Perissinotto, Eleonora / De Rosa, Antonio / Ceccon, Carlotta / Gasparello, Jessica / Denaro, Luca / D'Amico, Alberto / Chioffi, Franco / Carcea, Elena / Fassan, Matteo / Lonardi, Sara

British journal of cancer

2024 Volume 130, Issue 8, Page(s) 1316–1323

Abstract: Background: Little is known about prognostic factors of brain metastases (BM) from colorectal cancer (CRC). HER2 amplification/overexpression (HER2+) was previously described; its impact on prognosis remains uncertain.: Methods: In the translational ... ...

Abstract	Background: Little is known about prognostic factors of brain metastases (BM) from colorectal cancer (CRC). HER2 amplification/overexpression (HER2+) was previously described; its impact on prognosis remains uncertain. Methods: In the translational study HEROES, extensive molecular analysis was performed on primary CRC (prCRC) and their matched resected BM by means of NGS comprehensive genomic profiling and HER2 status as assessed by immunohistochemical/ in situ hybridization. Count of tumour-infiltrating lymphocytes (TILs) was also performed. Primary objective: to describe the molecular landscape of paired BM/prCRC. Secondary objectives: to search for new prognostic biomarkers of outcome after BM resection: intracranial-only Progression-Free Survival (BM-iPFS), Progression-Free Survival (BM-PFS), and Overall Survival (BM-OS). Results: Out of 22 patients having paired samples of prCRC and BM, HER2+ was found on 4 (18%) BM, 3 (75%) of which also HER2+ in matched prCRC. Lower tumour mutation burden (HR 3.08; 95%CI 1.06-8.93; p = 0.0386) and HER2-negative BM (HER2neg) (HR 7.75;95%CI 1.97-30.40; p = 0.0033) were associated with longer BM-iPFS; HER2neg BM (HR 3.44; 95%CI 1.03-11.53; p = 0.0449) and KRAS Conclusions: This study shows HER2+ enrichment in both BM and their prCRC. TILs-enriched BM conferred better BM-OS.
MeSH term(s)	Humans ; Prognosis ; Genomics ; Brain Neoplasms/genetics ; Brain Neoplasms/surgery ; Brain Neoplasms/metabolism ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/surgery
Language	English
Publishing date	2024-02-12
Publishing country	England
Document type	Journal Article
ZDB-ID	80075-2
ISSN	1532-1827 ; 0007-0920
ISSN (online)	1532-1827
ISSN	0007-0920
DOI	10.1038/s41416-023-02569-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.142: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito